Member access

4-Traders Homepage  >  Shares  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

NOVARTIS AG (NOVN)

212
Delayed Quote. Delayed CHI-X - 01/27 03:14:09 am
87.775 CHF   +0.89%
03:02aDJNovartis Upbeat Despite Weaker Profit -- Update
02:27a Novartis flags faster sales and profit growth for 2015
01:41aDJNOVARTIS : Posts Fall in Fourth-Quarter Profit
SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

UK's NICE Backs Novartis Eye Drug, Reversing Earlier Guidance

10/04/2012 | 07:16pm US/Eastern

By Marta Falconi

ZURICH--The U.K.'s health costs watchdog has reversed earlier guidance and now recommends eye drug Lucentis for a new use, after its maker Novartis AG (>> Novartis AG) offered a better price.

The U.K's National Institute for Health and Clinical Excellence, or NICE, recommends the drug for certain patients who suffer from visual impairment caused by diabetic macular oedema, the regulator said Friday. Without discount, Lucentis costs 742.17 pounds ($1,195) per injection and is given monthly, NICE said.

The new draft guidance is now up for consultation.

NICE decides if particular treatments should be used on the state-run National Health Service. The watchdog had previously rejected Lucentis for diabetic macular oedema, a condition caused by fluid collecting in the central part of the retina, which leads to blurred central vision and other problems.

The drug is already recommended to treat wet age-related macular degeneration.

Novartis said it was pleased with NICE's decision, but lamented the watchdog's move to restrict Lucentis to only those patients with more thickened retinas.

"This has undervalued the benefits that Lucentis provides to all patients with visual impairment due to diabetic macular oedema," the company said.

The Swiss company said it will continue to work with NICE and other health authorities until final draft guidance is issued by early 2013.

Lucentis, which generated nearly 2.05 billion Swiss francs ($2.19 billion) in sales in 2011, was co-developed by Novartis and Swiss rival Roche Holding AG (ROG.VX). Novartis markets the medicine outside the U.S.

Write to Marta Falconi at marta.falconi@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Novartis AG
React to this article
Latest news on NOVARTIS AG
03:02aDJNovartis Upbeat Despite Weaker Profit -- Update
02:27a Novartis flags faster sales and profit growth for 2015
01:41aDJNOVARTIS : Posts Fall in Fourth-Quarter Profit
01:02a NOVARTIS : delivered solid sales growth, margin expansion and pipeline progress ..
01/26 NOVARTIS : Alcon - Novartis National Sales Meeting Successfully Held at PEACH
01/26 NOVARTIS : drug Jakavi recommended by CHMP for EU approval to treat adults with ..
01/26 NOVARTIS : Bexsero vaccine approved by FDA for the prevention of meningitis B, t..
01/26 NOVARTIS : Receives FDA Approval for Cosentyx
01/24 NOVARTIS : Supreme Court Clarified Standard of Review for Patent Claim Construct..
01/24 NOVARTIS : Supreme Court Calls for Greater Deference to District Court Claim Con..
Advertisement
Chart
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF